Opinion|Videos|March 14, 2025
Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment
Panelists discuss how health care institutions have established structured care pathways for nonspecialist providers to evaluate mild cognitive impairment and mild dementia, incorporating validated questionnaires, standardized screening protocols, and clear referral guidelines to ensure consistent assessment across diverse clinical settings.
Video content above is prompted by the following:
- Have you created a care pathway for nonspecialist providers to use when evaluating patients for mild cognitive impairment or mild dementia?
- If so, can you describe the pathway? For example, do you use validated questionnaires or standardized screening protocols?
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5